Rigenerand receives regulatory approval for gene therapy production in Italy The italian biotech company Rigenerand has received received authorization from the Italian Medicine Authority (AIFA) to produce gene therapy medicinal products for clinical purposes. This approval enables Rigenerand to manufacture its own product, RR001, for the treatment of pancreatic cancer.…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their latest report:"AAV-based gene therapy Products: Ongoing Clinical Trials". This 205-page report provides you with a unique exhaustive overview of 116 ongoing trials for the treatment of 40 diseases (as of June 2020). More than 80 products from 49…..
A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies
A point of care center to be established in Madrid for the development of T-cell and dendritic cell-based therapies Orgenesis, a global US biotech company developing personalized therapies and closed processing systems through its Cell & Gene Therapy (CGT) Biotech Platform, announced a research and development collaboration with Hospital Infantil…..
Asklepios BioPharmaceutical (AskBio) has acquired BrainVectis, a French company dedicated to the development of gene therapy for neurodegenerative disorders. Founded in 2015, BrainVectis is a spin-off from French national institute for health and medical research (INSERM). Based on work carried out by Nathalie Cartier-Lacave and her team and collaborators…..
Trend Chart on Innovative Biotherapies - January 15th, 2020 FEATURE STORY ● The National Gene Vector Biorepository. Eleven years of providing resources to the gene therapy community GENE THERAPY ● Recommendations for the development of cell-based anti-viral vector neutralizing antibody assays DISRUPTIVE TECHNOLOGIES ● A small molecule-controlled Cas9 repressible system…..
Morpholino technology could allow control of gene therapy doses Scientists at Scripps Research, led by principal investigator Michael Farzan, have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing. The feat, reported in Nature Biotechnology, offers gene therapy designers what may…..
FEATURE STORY ● Artificial intelligence approach to create AAV capsids for gene therapies DISRUPTIVE TECHNOLOGIES ● Nanoparticles as carriers for drug delivery of macromolecules across the blood-brain barrier CLINICAL TRIALS - DATAS ● Libella gene therapeutics to run a patient paid trial of telomerase gene therapy M&A - AGREEMENTS ●…..
An artificial intelligence approach to create AAV capsids for gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the recent wave of gene therapies that are in development in academic and biotechnology laboratories (1). However, natural AAVs do not specifically…..
Two Chinese companies invest in Vigeneron, a German firm developing ophthalmological gene therapy programs
Two Chinese companies invest in Vigeneron, a German firm developing ophthalmological gene therapy programs The German gene therapy company Vigeneron has closed a series A financing round led by WuXi AppTec, a Chinese provider of R&D and manufacturing services and Sequoia Capital China, a venture capital firm based in Beijing.…..
More than 580 gene therapy products are under development in biotech and pharmaceutical companies for the treatment of more than 240 diseases. More than 200 of these products are now at the clinical stage. After releasing our « Landscape in… Gene Therapy Companies » in September, we now offer you an opportunity…..